David D. Eisenstat

David D. Eisenstat is a Professor at the University of Melbourne, Australia, serving as Director of the Children's Cancer Centre at the Royal Children's Hospital and Group Leader of Neuro-Oncology at the Murdoch Children's Research Institute. His clinical expertise spans Pediatric Hematology/Oncology and Neuro-Oncology, with a focus on childhood brain tumor treatment and research.

His research centers on molecular mechanisms of pediatric brain tumors, particularly gliomas. Key interests include p53 pathway dynamics in DNA damage response, biomarker discovery for targeted therapies (e.g., BCL2L1 methylation), and WHO CNS tumor classification systems. He pioneers applications of spatial transcriptomics in organoid models to map tumor microenvironments, bridging molecular biology with clinical neuro-oncology.

Recent publications (2024-2025) reveal a multidisciplinary approach integrating genomic profiling, immune modulation, and global health perspectives. His work spans basic science (UBE4B phosphorylation dynamics), clinical translation (MCL1 dependency predictors), and policy implementation (WHO guidelines in resource-limited settings), all aimed at improving outcomes for pediatric brain tumor patients.

As Group Leader at Murdoch Children's Research Institute, he directs a team advancing neuro-oncology through molecular characterization of tumors and clinical trial development. His editorial roles as Specialty Chief Editor for Frontiers in Neurology/Oncology and Review Editor for epigenetics journals highlight his leadership in disseminating cutting-edge research across oncology and molecular science domains.